Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 11, 2003. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific share transactions and does not contain financial performance data.
Material Changes
The primary material change reported is a transaction involving the GlaxoSmithKline Employee Trust ("the GSK Trust"). On August 8, 2003, Abacus (GSK) Trustees Limited transferred 7,100 Ordinary Shares on behalf of participants in the SmithKline Beecham Employee Share Option Plan 1991. The company was advised of this transaction on August 11, 2003.
Outlook, Risks, and Management Commentary
The filing does not contain guidance, outlook, management commentary on business strategy, or discussions of risks and contingencies. It notes that the GSK Trust is a discretionary trust where all employees or former employees are potential beneficiaries. Consequently, directors Dr. J-P Garnier and Mr. J D Coombe hold an interest in the shares held by the trust in the same capacity as other employees.
Key Facts for Investor Verification
- 7,100 Ordinary Shares were transferred by the GSK Trust on August 8, 2003.
- The transaction relates to the SmithKline Beecham Employee Share Option Plan 1991.
- Directors Dr. J-P Garnier and Mr. J D Coombe have an indirect interest in these shares via the trust.
- No financial performance metrics are disclosed in this specific filing.